bimatoprost
Phase 2- Indications
- Glaucoma, Ocular hypertension
Company intelligence / Profile preview
ForSight VISION5
Menlo Park, California, United Statesversantventures.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Phase II study showed a single administration of the ring provided sustained reduction in IOP for six months with a reduction of 4-6 mmHg at the primary endpoint of 12 weeks. Approximately 90% of subjects retained inserts in both eyes for six months without clinician assistance[5].
- Therapeutic areas
- ImmunologyOphthalmology
- Modalities
- Drug delivery device (peri-ocular ring)
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on ForSight VISION5.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ForSight VISION5.